Aziyo Biologics Stock Fundamentals
AZYODelisted Stock | USD 2.44 0.00 0.00% |
Aziyo Biologics fundamentals help investors to digest information that contributes to Aziyo Biologics' financial success or failures. It also enables traders to predict the movement of Aziyo Stock. The fundamental analysis module provides a way to measure Aziyo Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aziyo Biologics stock.
Aziyo |
Aziyo Biologics Company Current Valuation Analysis
Aziyo Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Aziyo Biologics Current Valuation | 40.69 M |
Most of Aziyo Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aziyo Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Aziyo Biologics has a Current Valuation of 40.69 M. This is 99.72% lower than that of the Health Care Equipment & Supplies sector and 99.67% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.76% higher than that of the company.
Aziyo Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aziyo Biologics's current stock value. Our valuation model uses many indicators to compare Aziyo Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aziyo Biologics competition to find correlations between indicators driving Aziyo Biologics's intrinsic value. More Info.Aziyo Biologics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aziyo Biologics' earnings, one of the primary drivers of an investment's value.Aziyo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aziyo Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aziyo Biologics could also be used in its relative valuation, which is a method of valuing Aziyo Biologics by comparing valuation metrics of similar companies.Aziyo Biologics is currently under evaluation in current valuation category among its peers.
Aziyo Fundamentals
Return On Equity | -7.75 | |||
Return On Asset | -0.29 | |||
Profit Margin | (0.70) % | |||
Operating Margin | (0.50) % | |||
Current Valuation | 40.69 M | |||
Shares Outstanding | 11.92 M | |||
Shares Owned By Insiders | 2.18 % | |||
Shares Owned By Institutions | 70.44 % | |||
Number Of Shares Shorted | 68.02 K | |||
Price To Book | 13.34 X | |||
Price To Sales | 1.29 X | |||
Revenue | 49.19 M | |||
Gross Profit | 19.22 M | |||
EBITDA | (22.38 M) | |||
Net Income | (32.9 M) | |||
Cash And Equivalents | 16.49 M | |||
Cash Per Share | 1.21 X | |||
Total Debt | 34.89 M | |||
Debt To Equity | 3.50 % | |||
Current Ratio | 1.00 X | |||
Book Value Per Share | (1.36) X | |||
Cash Flow From Operations | (21.43 M) | |||
Short Ratio | 3.98 X | |||
Earnings Per Share | (2.18) X | |||
Target Price | 10.5 | |||
Number Of Employees | 151 | |||
Beta | -0.18 | |||
Market Capitalization | 23.72 M | |||
Total Asset | 68.84 M | |||
Retained Earnings | (137.99 M) | |||
Working Capital | 8.08 M | |||
Z Score | -2.62 | |||
Net Asset | 68.84 M |
About Aziyo Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aziyo Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aziyo Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aziyo Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic devicecardiovascular, orthopedicspinal repair, and soft tissue reconstruction markets. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland. Aziyo Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 162 people.
Pair Trading with Aziyo Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aziyo Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aziyo Biologics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aziyo Stock
Moving against Aziyo Stock
0.5 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.5 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
0.49 | PPERF | Bank Mandiri Persero | PairCorr |
0.47 | BKRKF | PT Bank Rakyat | PairCorr |
0.35 | BKRKY | Bank Rakyat | PairCorr |
The ability to find closely correlated positions to Aziyo Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aziyo Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aziyo Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aziyo Biologics to buy it.
The correlation of Aziyo Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aziyo Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aziyo Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aziyo Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Aziyo Stock
If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Transaction History View history of all your transactions and understand their impact on performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |